Results 21 to 30 of about 14,439 (224)

Biosimilars in rheumatoid arthritis in 2022 – data from the Romanian Registry of Rheumatic Diseases [PDF]

open access: yesRomanian Journal of Rheumatology, 2023
Objective. The study aimed at determining whether RA patients starting or stopping biosimilars differ in any regard from those starting or stopping originals. Methods.
Horatiu Popoviciu   +8 more
doaj   +1 more source

Biosimilars in Oncology: Latest Trends and Regulatory Status [PDF]

open access: yes, 2022
Biologic-based medicines are used to treat a variety of diseases and account for around one-quarter of the worldwide pharmaceutical market. The use of biologic medications among cancer patients has resulted in substantial advancements in cancer treatment
Sukriti Vishwas   +44 more
core   +1 more source

Pharmacists' confidence in explaining biosimilars to patients before a nationwide medicine change: A cross-sectional study

open access: yesExploratory Research in Clinical and Social Pharmacy, 2022
Background: Biosimilars can improve patient access to biological medicines. Although biosimilars have been shown to be equally effective and safe, some patients remain reluctant to transition to biosimilars.
Chiara Gasteiger   +2 more
doaj   +1 more source

Analysis of Suffix Use for Biosimilar Product Identification in Postmarketing Adverse Event Reporting. [PDF]

open access: yesClin Pharmacol Ther
Accurate identification of medicines used in adverse event reports is crucial for effective postmarketing safety surveillance. The US Food and Drug Administration's (FDA) four‐letter suffix naming convention was designed to facilitate accurate biological product identification, but the extent to which these suffixes have been incorporated into ...
Stojanovic D   +3 more
europepmc   +2 more sources

Biosimilars: potential implications for clinicians [PDF]

open access: yes, 2016
With the expiration of patent protection for several biologics looming, the production of highly similar therapeutic agents has begun to emerge on the pharmaceutical market. These alternative drugs are referred to as biosimilars. Many anticipate that the
Eleryan, Misty G.   +7 more
core   +2 more sources

Biosimilars [PDF]

open access: yes, 2022
Introduced in the 1980s, biologic medications have since become important tools in modern medicine. However, biologics are expensive, greatly affecting the healthcare budgets of both underdeveloped and developed countries. Fortunately, biosimilars, which

core   +1 more source

Ever-changing landscape of biosimilars in Canada; findings and implications from a global perspective [PDF]

open access: yes, 2019
Siu et al. have comprehensively assessed the rapidly changing regulation and reimbursement environment for biologicals and biosimilars in Canada and the resultant ...
Allocati, Eleonora   +2 more
core   +5 more sources

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

open access: yesArthritis Research & Therapy, 2020
Background ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated.
Mark C. Genovese   +9 more
doaj   +1 more source

Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients

open access: yesTherapeutic Advances in Gastroenterology, 2021
Background: In this analysis we aimed to describe Brazilian inflammatory bowel disease (IBD) patients’ knowledge and perceptions regarding biosimilars and compare with viewpoints from non-Brazilian patients.
Karoline Soares Garcia   +8 more
doaj   +1 more source

Biosimilars [PDF]

open access: yesTherapeutische Umschau, 2011
Die Bewertung von Biosimilars stellt eine Herausforderung für alle an der Zulassung und an der Arzneimittelauswahl Beteiligten im Gesundheitswesen dar. Bewertungskriterien sind wie bei allen Arzneimitteln Qualität, Wirksamkeit, Sicherheit/Verträglichkeit und Wirtschaftlichkeit.
openaire   +6 more sources

Home - About - Disclaimer - Privacy